{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-200747","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2025-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.278548+00:00","generated_at":"2026-05-17T06:52:41.516094+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Clearside Biomedical files 1-for-15 reverse stock split, reduces authorized shares to 26.7M","bullets":["Reverse stock split effective September 12, 2025 at 5:00 p.m. ET; split-adjusted trading begins September 15, 2025.","Every 15 outstanding shares combine into 1; no fractional shares issued – cash in lieu.","Authorized common stock reduced from 400M to 26,666,666; par value unchanged at $0.001.","Proportionate adjustments to stock options, RSUs, warrants, and equity plan reserves.","New CUSIP 185063203; Nasdaq ticker CLSD unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-200747","json":"https://secwatch.observer/filing/0001193125-25-200747.json","markdown":"https://secwatch.observer/filing/0001193125-25-200747.md","text":"https://secwatch.observer/filing/0001193125-25-200747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000119312525200747/0001193125-25-200747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000119312525200747/clsd-20250910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:52:41.516094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ed268df814cde9e8ae15ead43f1e1e87d54efcb","claim":"Clearside Biomedical, Inc.: Filed a Certificate of Amendment to effect a 1-for-15 reverse stock split and reduce authorized shares from 400,000,000 to 26,666,666 (effective 2025-09-12).","evidence_excerpt":"On September 10, 2025, Clearside Biomedical, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “ Amendment ”) with the Secretary of State of the State of Delaware to effect a one-for-fifteen (1-for-15) reverse stock split (the “ Reverse Stock Split ”) of its outstanding common stock and a reduction in the total number of authorized shares of its common stock from 400,000,000 to 26,666,666 (the “ Shares Reduction ”). The Amendment will be effective at 5:00 p.m. Eastern Time on September 12, 2025.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000119312525200747/0001193125-25-200747-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-09-12"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}